BOTHELL, Wash., May 31, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences:
Jefferies Healthcare Conference
Fireside Chat on Wednesday, June 7, 2023, at 8:30 a.m. ET in New York
Goldman Sachs 44th Annual Global Healthcare Conference
Presentation on Wednesday, June 14, 2023, at 8:40 a.m.PT in Dana Point, California
Live webcasts of the Jefferies fireside chat and Goldman Sachs presentation can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations-investor. An archived replay of the webcasts will be available for at least 30 days following the event.
About Athira Pharma, Inc.
Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with its novel mechanism of action. Athira is currently advancing its pipeline of therapeutic candidates targeting the HGF/MET neurotrophic system for Alzheimer’s and Parkinson’s disease, Dementia with Lewy bodies and amyotrophic lateral sclerosis (ALS). For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn, Twitter and @athirapharma on Instagram.
Investor & Media Contact:
Julie Rathbun
Athira Pharma
Julie.rathbun@athira.com
206-769-9219
| Last Trade: | US$0.26 |
| Daily Change: | -0.02 -7.14 |
| Daily Volume: | 320,297 |
| Market Cap: | US$10.050M |
May 09, 2025 February 27, 2025 November 07, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
